NCT04362007View on ClinicalTrials.gov

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
Interventions
DRUG

ASTX660

Treatment of ASTX660 for r/r PTCL and r/r CTCL

DRUG

ASTX660

Treatment of ASTX660 for r/r ATLL

DRUG

ASTX660

Treatment of ASTX660 for r/r PTCL

Trial Locations (1)

Unknown

Yamagata University Hospital, Yamagata

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT04362007 - A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | Biotech Hunter | Biotech Hunter